(Q35114267)

6 August 2017

1 reference

title

Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics (English)

1 reference

6 August 2017

Non-alcoholic fatty liver disease: lumen–liver interactions and possible role for probiotics (English)

1 reference

https://api.crossref.org/works/10.1016/S0168-8278(03)00097-7

27 December 2023

0 references

0 references

metabolic dysfunction–associated steatotic liver disease

1 reference

non-alcoholic fatty liver

inferred from title

1 reference

1 reference

Steven F. Solga

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12713883

27 December 2023

A. M. Diehl

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12713883

27 December 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12713883

27 December 2023

publication date

1 May 2003

1 reference

full work available at URL

6 August 2017

http://www.journal-of-hepatology.eu/article/S0168827803000977/pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12713883

https://api.elsevier.com/content/article/PII:S0168827803000977?httpAccept=text/xml

27 December 2023

1 reference

https://api.crossref.org/works/10.1016/S0168-8278(03)00097-7

https://api.elsevier.com/content/article/PII:S0168827803000977?httpAccept=text/plain

27 December 2023

1 reference

https://api.crossref.org/works/10.1016/S0168-8278(03)00097-7

27 December 2023

published in

Journal of Hepatology

1 reference

6 August 2017

38

1 reference

6 August 2017

681-687

1 reference

6 August 2017

5

1 reference

Intestinal endotoxins as mediators of hepatic injury--an idea whose time has come again

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Prevalence of and risk factors for hepatic steatosis in Northern Italy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Cytokine regulation of liver injury and repair

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Steatohepatitis: a tale of two "hits"?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Non-alcoholic fatty liver: another feature of the metabolicsyndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Association of nonalcoholic fatty liver disease with insulin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Peroxisomal beta-oxidation and steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Mitochondria in steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Mitochondrial adaptations to obesity-related oxidant stress

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Infection of hypercholesterolemic mice with Coxsackievirus B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Etiopathogenesis of nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Antibiotics prevent liver injury in rats following long-term exposure to ethanol

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver (disease)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Fatty liver vulnerability to endotoxin-induced damage despite NF-kappaB induction and inhibited caspase 3 activation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Is bacterial ash the flash that ignites NASH?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Role of Kupffer cells and gut-derived endotoxins in alcoholic liver injury

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

The OB protein (leptin) pathway--a link between adipose tissue mass and central neural networks

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Animal models of steatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Long-term consequences after jejunoileal bypass for morbid obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Recurrence of nonalcoholic steatohepatitis following liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Diabetes and the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Long-Term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Treatment of nonalcoholic fatty liver: present and emerging therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

The role of probiotic cultures in the control of gastrointestinal health

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Probiotics in infective diarrhoea and inflammatory bowel diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Complementary and alternative medicine in chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Probiotic bacteria enhance murine and human intestinal epithelial barrier function

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Probiotic supplementation reduces the risk of bacterial translocation in experimental short bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Effect of Lactobacillus johnsonii La1 and antioxidants on intestinal flora and bacterial translocation in rats with experimental cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Effect of Lactobacillus supplementation with and without arginine on liver damage and bacterial translocation in an acute liver injury model in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Effects of different probiotic strains of Lactobacillus and Bifidobacterium on bacterial translocation and liver injury in an acute liver injury model

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Probiotics and inflammatory bowel disease: is there a scientific rationale?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Probiotics: a role in the treatment of intestinal infection and inflammation?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Probiotics in the management of atopic eczema

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Gut-liver axis: a new point of attack to treat chronic liver damage?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900097-7

7 January 2021

Identifiers

1 reference

6 August 2017

1 reference